Beyond Air Enters Material Agreement, Reports Equity Sales
Ticker: XAIR · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1641631
| Field | Detail |
|---|---|
| Company | Beyond Air, Inc. (XAIR) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $11,500,00, $0.3793 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financial-obligation
TL;DR
Beyond Air just signed a big deal and sold some stock. Watch this space.
AI Summary
On September 27, 2024, Beyond Air, Inc. entered into a material definitive agreement related to the creation of a direct financial obligation. The company also reported unregistered sales of equity securities. This filing follows a period of significant corporate activity, including previous name changes from AIT Therapeutics, Inc. and KokiCare, Inc.
Why It Matters
This filing indicates new financial commitments and equity transactions for Beyond Air, Inc., which could impact its financial structure and shareholder base.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial obligations and dilutive effects.
Key Players & Entities
- Beyond Air, Inc. (company) — Registrant
- September 27, 2024 (date) — Date of earliest event reported
- AIT Therapeutics, Inc. (company) — Former company name
- KokiCare, Inc. (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by Beyond Air, Inc. on September 27, 2024?
The filing indicates the entry into a material definitive agreement that results in the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant.
What type of securities were sold in the unregistered sales reported by Beyond Air, Inc.?
The filing reports unregistered sales of equity securities, but the specific type of equity is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 27, 2024.
What were the previous names of Beyond Air, Inc.?
Beyond Air, Inc. was formerly known as AIT Therapeutics, Inc. and KokiCare, Inc.
What is the primary business of Beyond Air, Inc. according to its SIC code?
Beyond Air, Inc. is classified under SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus.
Filing Stats: 666 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2024-10-02 17:00:24
Key Financial Figures
- $11,500,00 — expected terms: (i) principal amount of $11,500,00; (ii) ten-year term; (iii) interest of
- $0.3793 — 's common stock at an exercise price of $0.3793 per share. The Company expects to enter
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-039221.txt ( ) — 208KB
- xair-20240927.xsd (EX-101.SCH) — 3KB
- xair-20240927_lab.xml (EX-101.LAB) — 33KB
- xair-20240927_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEYOND AIR, Inc. Date: October 2, 2024 By: /s/ Steven A. Lisi Name: Steven A. Lisi Title: Chief Executive Officer